{"id":"paclitaxel-bevacizumab-atezolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel stabilizes microtubules to induce apoptosis in rapidly dividing cancer cells. Bevacizumab blocks VEGF signaling to inhibit angiogenesis and reduce tumor vasculature. Atezolizumab blocks PD-L1 on tumor cells and immune cells, releasing the brake on T-cell-mediated anti-tumor immunity. The combination aims to provide synergistic anti-tumor effects through chemotherapy, anti-angiogenesis, and immunotherapy.","oneSentence":"This combination uses a chemotherapy agent (paclitaxel) to kill cancer cells, an anti-angiogenic antibody (bevacizumab) to block tumor blood vessel formation, and an immune checkpoint inhibitor (atezolizumab) to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:59.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT03768063","phase":"PHASE3","title":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-02-28","conditions":"Cancer","enrollment":1000},{"nctId":"NCT05249426","phase":"PHASE1","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-04-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":48},{"nctId":"NCT03181100","phase":"PHASE2","title":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-27","conditions":"Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT05112965","phase":"PHASE3","title":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-12-01","conditions":"Neoplasms","enrollment":49},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":"Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation","enrollment":133},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT05781308","phase":"PHASE2","title":"Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2023-04-26","conditions":"Non Small Cell Lung Cancer","enrollment":156},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT07093762","phase":"","title":"Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Fuzhou General Hospital","startDate":"2025-08-20","conditions":"Non Small Cell Lung Cancer","enrollment":35},{"nctId":"NCT03353831","phase":"PHASE3","title":"Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer","status":"COMPLETED","sponsor":"AGO Research GmbH","startDate":"2018-09-11","conditions":"Recurrent Ovarian Carcinoma","enrollment":574},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT02891824","phase":"PHASE3","title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2016-09-22","conditions":"Ovarian Cancer","enrollment":614},{"nctId":"NCT04732598","phase":"PHASE3","title":"A Phase III Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Japanese Foundation for Cancer Research","startDate":"2021-01-21","conditions":"Breast Cancer","enrollment":280},{"nctId":"NCT06793553","phase":"PHASE2","title":"Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC","status":"RECRUITING","sponsor":"Japan Breast Cancer Research Group","startDate":"2024-09-13","conditions":"Metastatic Breast Cancer","enrollment":106},{"nctId":"NCT03556839","phase":"PHASE3","title":"Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-09-25","conditions":"Carcinoma of the Cervix, Stage IVB","enrollment":410},{"nctId":"NCT04245085","phase":"PHASE2","title":"ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2020-09-29","conditions":"EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC","enrollment":95},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT04194203","phase":"PHASE3","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":305},{"nctId":"NCT04408118","phase":"PHASE2","title":"First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-05","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Triple Negative Breast Cancer","enrollment":100},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT03961698","phase":"PHASE2","title":"Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2019-12-17","conditions":"Breast Cancer, Renal Cell Carcinoma","enrollment":91},{"nctId":"NCT03991403","phase":"PHASE3","title":"Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2019-08-27","conditions":"Non-small Cell Lung Cancer","enrollment":228},{"nctId":"NCT03038100","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-03-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1301},{"nctId":"NCT02366143","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-03-31","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1202},{"nctId":"NCT03394885","phase":"PHASE1, PHASE2","title":"Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-06-19","conditions":"Ovarian Cancer, Ovarian Neoplasms","enrollment":18},{"nctId":"NCT02715531","phase":"PHASE1","title":"A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-06","conditions":"Solid Tumor","enrollment":243},{"nctId":"NCT01633970","phase":"PHASE1","title":"A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-07-11","conditions":"Cancer","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel + bevacizumab + atezolizumab","genericName":"Paclitaxel + bevacizumab + atezolizumab","companyName":"Japanese Foundation for Cancer Research","companyId":"japanese-foundation-for-cancer-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a chemotherapy agent (paclitaxel) to kill cancer cells, an anti-angiogenic antibody (bevacizumab) to block tumor blood vessel formation, and an immune checkpoint inhibitor (atezolizumab) to enhance anti-tumor immune responses. Used for Non-small cell lung cancer (phase 3 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}